Guidelines for the management of tumor-associated hyperglycemia (2021 edition)

中国抗癌协会肿瘤内分泌专业委员会; 重庆市中西医结合学会肿瘤内分泌分会

doi:10.19401/j.cnki.1007-3639.2021.07.013

您当前的位置：

首页 >

文章列表页 >

Guidelines for the management of tumor-associated hyperglycemia (2021 edition)

更新时间：2025-12-31

- Guidelines for the management of tumor-associated hyperglycemia (2021 edition)
- China Oncology Vol. 31, Issue 7, Pages: 651-688(2021)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2021.07.013
  CLC：
- Published Online：04 August 2021，
  
  Published：04 August 2021
- 稿件说明：
移动端阅览
中国抗癌协会肿瘤内分泌专业委员会, 重庆市中西医结合学会肿瘤内分泌分会. 肿瘤相关性高血糖管理指南（2021年版）[J]. 中国癌症杂志, 2021, 31(7): 651-688.

中国抗癌协会肿瘤内分泌专业委员会, 重庆市中西医结合学会肿瘤内分泌分会. Guidelines for the management of tumor-associated hyperglycemia (2021 edition)[J]. China Oncology, 2021, 31(7): 651-688.
中国抗癌协会肿瘤内分泌专业委员会, 重庆市中西医结合学会肿瘤内分泌分会. 肿瘤相关性高血糖管理指南（2021年版）[J]. 中国癌症杂志, 2021, 31(7): 651-688. DOI： 10.19401/j.cnki.1007-3639.2021.07.013.

中国抗癌协会肿瘤内分泌专业委员会, 重庆市中西医结合学会肿瘤内分泌分会. Guidelines for the management of tumor-associated hyperglycemia (2021 edition)[J]. China Oncology, 2021, 31(7): 651-688. DOI： 10.19401/j.cnki.1007-3639.2021.07.013.

摘要

恶性肿瘤逐渐成为中国最常见的威胁生命的慢性非传染性疾病，近年来研究发现，恶性肿瘤与高血糖及糖尿病关系密切。一方面，高血糖和糖尿病可以增加多种恶性肿瘤的发病率，且与其不良预后密切相关。另一方面，部分肿瘤本身可导致高血糖和糖尿病。此外，在治疗恶性肿瘤的过程中也会出现高血糖和糖尿病。以上统称为肿瘤相关性高血糖，但目前尚无相关的指南可用于指导临床诊治和管理。中国抗癌协会肿瘤内分泌专业委员会和重庆市中西医结合学会肿瘤内分泌分会组织专家对肿瘤相关性高血糖的研究进展进行归纳总结，旨在及时传递重要信息，指导临床实践。本指南主要涵盖肿瘤相关性高血糖的概述、临床诊治管理和长期随访管理，将有助于临床医师对肿瘤相关性高血糖患者进行规范化管理，改善中国肿瘤相关性高血糖患者的临床结局。

Abstract

Malignant tumors have gradually become the most common chronic non-communicable diseases in China. Recent research has indicated that malignant tumors are closely associated with hyperglycemia and diabetes. On one hand

hyperglycemia and diabetes increased the morbidity of many malignant tumors

and are related to their poor prognosis. On the other hand

some tumors can also cause hyperglycemia and diabetes. In addition

hyperglycemia and diabetes may occur during the treatment of malignant tumor. These are all described as tumor-associated hyperglycemia. However there is no relevant guidance for clinical diagnosis

treatment and management. Experts from the Onco-endocrinology Society of Chinese Anti-Cancer Association and Onco- endocrinology Society of ChongQing Integrative Medicine Association summarized the research progress of tumor-associated hyperglycemia

aimed to transmit recent important progress and guide clinical practice. This guideline mainly covered the overview of tumor-associated hyperglycemia

clinical diagnosis

treatment and long-term follow-up management. This guideline may help clinicians to standardize the management of patients with tumor-associated hyperglycemia

and improve the clinical outcomes of patients with tumor-associated hyperglycemia in China.

关键词

Keywords

references

Views

1788

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Interpretation of Guidelines for the Management of Tumor-associated Hyperglycemia (2021 edition)

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer

Important research progress in clinical practice for early breast cancer in 2024

Comprehensive management strategy of interstitial lung disease induced by trastuzumab deruxtecan

Important research progress in clinical practice for early breast cancer in 2023

Related Author

童南伟

吴绮楠

Jugao FANG

Qian SHI

Feng JIN

Xinmiao YU

Ziqi PENG

Xing LI

Related Institution

四川大学华西医院内分泌代谢病科

重庆医科大学附属大足医院（大足区人民医院）内分泌科

Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University

Department of Breast Surgery, the First Affiliated Hospital of China Medical University

Department of Oncology, Affiliated Hospital of Jiangnan University

AI问答

⁰